Product Information
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB is a generic product labeled by Solco Healthcare US LLC, priced at $0.1488 per EA under NDC 43547033009. Its NADAC has been published 625 times since Oct 15, 2014.
FDA first approved this application on May 9, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5; 150 mg/1; mg/1
Manufacturer
Solco Healthcare US LLCNDC
43547033009
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA203072FDA Approved
5/9/2014
TE Code
AB
On Market Since
3/1/2014
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has been published 625 times since Oct 15, 2014, and over the history we have for it it has declined 54.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1488 per EA |
|---|---|
| All-time high | $0.3364 (Nov 12, 2014) |
| All-time low | $0.1308 (Jul 17, 2024) |
| 52-week high | $0.1696 |
| 52-week low | $0.1488 |
| Median price | $0.2419 |
| Average price | $0.2317 |
| Largest weekly change | +39.6% (Aug 21, 2024) |
| Weeks tracked | 625 |
| Tracking since | Oct 15, 2014 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solco Healthcare US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Irbesartan and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB, manufactured by Solco Healthcare US LLC, is $0.1488 per EA (NDC 43547033009), effective Sep 30, 2026.
How has the price of IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has declined 54.9%. It has been tracked across 625 weekly CMS publications since Oct 15, 2014.
What are the highest and lowest recorded NADAC prices for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
Since Oct 15, 2014, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has ranged from a low of $0.1308 (Jul 17, 2024) to a high of $0.3364 (Nov 12, 2014), with a median of $0.2419 per EA.
Are there cheaper alternatives to IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB, is $0.1405 per EA — about 6% below IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB.
Who manufactures IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB (NDC 43547033009) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.